Zealand Pharma is an international biotechnology company headquartered in Denmark that develops peptide-based and small-molecule medicines, with operations in Boston. It is listed on Nasdaq Copenhagen under the ticker ZEAL.
The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Zealand Pharma reported full-year 2025 revenue of DKK 9.2 billion, bolstered by a significant upfront payment from Roche. The company ended the year with DKK 15.1 billion in cash and set 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589686 |
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07338214 |
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations |
COMPLETED | PHASE1 |
| NCT07228403 |
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07197944 |
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS |
RECRUITING | PHASE3 |
| NCT07076030 |
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function |
COMPLETED | PHASE1 |
| NCT06926842 |
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06758583 |
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide |
COMPLETED | PHASE1 |
| NCT06682975 |
A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants |
RECRUITING | PHASE1 |
| NCT06662539 |
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities |
COMPLETED | PHASE2 |
| NCT06000891 |
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 |
TERMINATED | PHASE1 |
